Hyperprolactinaemia and prolactinoma

Exam relevance: in 8 of more than 150 board exam reports · rank 82

Synonyms
high prolactin, prolactinoma
Specialty
Gynaecology · Endocrinology & cycle
Images
Histology & cytology 2
Exam relevance
8 of more than 150 reports · rank 82
In the app
1 flashcard · GynFuchs
Last updated
10/2026 · Dr. Pascal Bafteh
Contents
  1. Images (2)
  2. Definition
  3. Classification
  4. Occurrence & epidemiology
  5. Aetiopathogenesis
  6. Clinical features
  7. Diagnosis
  8. Treatment principles
  9. Keep learning in the app
  10. Further reading (selection)
  11. Cross-references

Images (2)

Hyperprolactinaemia and prolactinoma – Histology (H&E): prolactinoma – solid pituitary adenoma of monomorphic chromophobe cells with round nucleiHistology & cytology
Histology (H&E): prolactinoma – solid pituitary adenoma of monomorphic chromophobe cells with round nucleiImage: Jensflorian, “PRL HE histology” (Wikimedia Commons) · CC BY-SA 3.0 · Source
Hyperprolactinaemia and prolactinoma – histology/cytology: Prolactin immunohistochemistry: diffuse cytoplasmic prolactin expression in the adenoma cells (perinuclear accentuation)Histology & cytology
Prolactin immunohistochemistry: diffuse cytoplasmic prolactin expression in the adenoma cells (perinuclear accentuation)Image: Jensflorian, “PRL IHC pituitary adenoma” (Wikimedia Commons) · CC BY-SA 3.0 · Source
1 / 2

Definition

Prolactinoma

  • Definition of the size limit: microprolactinoma < 10 mm, macroprolactinoma ≥ 10 mm.
  • What is additionally checked for a macroadenoma: visual field (chiasm proximity).
  • Hyperprolactinaemia is a raised serum prolactin concentration; a prolactinoma is a benign pituitary adenoma composed of lactotroph cells and the most common hormone-secreting pituitary tumour.

Classification

  • By size, microprolactinomas below 10 mm, macroprolactinomas above 10 mm and giant prolactinomas above 4 cm are distinguished.

Occurrence & epidemiology

Epidemiology

  • Prolactinomas account for about 40% of all pituitary tumours; between the ages of 20 and 50, women are affected about ten times more often than men, and microadenomas predominate in women.

Aetiopathogenesis

Aetiology and pathogenesis

  • Physiological causes include pregnancy, the postpartum period, nipple stimulation, stress, sleep and sexual intercourse.
  • Pharmacological causes include dopamine receptor blockers such as risperidone, haloperidol and metoclopramide, antidepressants such as tricyclics and fluoxetine, as well as opioids and oestrogens.
  • Besides prolactinoma, pathological causes include lesions of the hypothalamus and pituitary stalk, such as a stalk effect from non-functioning tumours, chronic renal failure, liver cirrhosis and primary hypothyroidism via raised TRH.

Clinical features

Clinical Presentation and Initial Steps

  • Typical symptoms: galactorrhoea, cycle disorders/amenorrhoea, infertility.
  • Why the cycle is disturbed: suppression of pulsatile GnRH secretion.
  • Most common cause in practice: drugs (neuroleptics, MCP, antidepressants).
  • Therefore, first: medication history.
  • Other causes: hypothyroidism, renal insufficiency, stress.
  • Before imaging, one determines: TSH, free thyroid levels, control value.
  • In women, galactorrhoea, oligo- or amenorrhoea and infertility predominate; oestrogen deficiency may cause dyspareunia, reduced libido and low bone density up to osteoporosis.
  • Space-occupying macroadenomas cause headache, visual field defects, cranial nerve deficits and hypopituitarism; these mass effects predominate mainly in men.

Diagnosis

  • Baseline investigations include serum prolactin as well as TSH and T4.
  • In prolactinoma, prolactin is typically raised to more than five times normal and correlates with tumour size, whereas non-functioning masses usually do not raise prolactin above three to four times normal.
  • Macroprolactin, a prolactin isoform of higher molecular weight and reduced bioactivity, can explain raised values without symptoms; with very large tumours and only modestly raised prolactin, a hook effect can produce falsely low values, revealed by dilution of the sample.
  • Contrast-enhanced MRI of the pituitary demonstrates the adenoma, complemented by visual field testing in macroadenomas.

Treatment principles

  • First, drug causes, hypothyroidism and pregnancy are excluded; drug-induced elevations are corrected by switching medication where possible.
  • In prolactinoma, dopamine agonists are first-line even for macroadenomas; surgery is indicated for intolerance, lack of response or persistent compression of the visual pathway.
  • An asymptomatic microprolactinoma in a woman not wishing to conceive can be observed under monitoring.

Specific treatment regimens with drugs and doses are covered in the GynFuchs app.

Keep learning in the app

In the GynFuchs app you can learn Hyperprolactinaemia and prolactinoma with flashcards, exam questions and image tasks (colposcopy, ultrasound, CTG) – free, in your browser or as an app.

In the app: 1 flashcard on this topic

Open in browser  About GynFuchs →

Further reading (selection)

  1. MSD Manual Professional: Prolactinoma
  2. StatPearls: Prolactinoma (NCBI Bookshelf)
  3. Approach to the Patient With Prolactinoma
  4. DocCheck Flexikon, Hyperprolaktinämie

Cross-references

Keep learning: test yourself

One question from the GynFuchs app on Hyperprolactinaemia and prolactinoma – tap an answer.

Question 1 of 1

A 32-year-old patient presents with menstrual irregularities and galactorrhoea in the context of subfertility. Is this statement true? “Prolactin suppresses pulsatile GnRH secretion, thereby disrupting ovulation.”

Answer

Correct: True. Elevated prolactin levels inhibit the pulsatile release of gonadotropin-releasing hormone (GnRH). This leads to impaired follicular maturation and anovulation, which disrupts the menstrual cycle.

More questions like these – with explanations and spaced repetition – in the app.

Note: Learning content from the GynFuchs app (flashcards, exam questions, image cases) for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.